Marks, Reinhard and Potthoff, Karin and Hahn, Joachim and Ihorst, Gabriele and Bertz, Hartmut and Spyridonidis, Alexandros and Holler, Ernst and Finke, Juergen M. (2008) Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. BLOOD, 112 (2). pp. 415-425. ISSN 0006-4971,
Full text not available from this repository. (Request a copy)Abstract
Toxicity-reduced conditioning is being used for allogeneic stem cell transplantation in older and/or comorbid patients. We report on the treatment of 133 patients (median age: 55.6 years [23-73 years]) with acute myelold leukemia (AML)/myelodysplastic syndrome (MDS; In = 81), myeloprol iterative syndromes (MPS; n = 20), and lymphoid malignancies (n = 32) using conditioning with FBIVI: fludarabine (5 x 30 mg/m(2)), 1,3-bis(2-chloroethyl)-lnitrosourea (or carmustine, BCNU; 2 x 200 Mg/M2), and melphalan (140 mg/m(2)). Patients 55 years or older received fludarabine with reduced BCNU (2 x 150 mg/m(2)) and melphalan (110 mg/m(2)). After engraftment, chimerism analyses revealed complete donor hematopoiesis in 95.7% of patients. With a median followup of 58.5 months, 3- and 5-year overall survival (OS) was 53.0% and 46.1 %, eventfree survival (EFS) was 46.4% and 41.9%. No significant differences in OS and EFS were evident considering disease status (early vs advanced), patient age (< 55 vs >= 55 years), or donor type (related vs unrelated) in univariate and multivariate analyses. The cumulative 5-year incidence of death due to relapse was 20.1 %. Nonrelapse mortality (NRM) after 100 days and 1 year was 15.8% and 26.3%. Among patients with AMUMDS, advanced cases (n = 64, including 61 with active disease) showed an OS of 44.6% and 42.4% after 3 and 5 years, respectively. Therefore, FBIVI conditioning combines effective disease control with low NRM.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; REGIMEN-RELATED TOXICITY; MYELODYSPLASTIC SYNDROME; UNRELATED DONORS; OLDER PATIENTS; INTENSITY; THERAPY; GRAFT; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 28 Oct 2020 08:05 |
| Last Modified: | 28 Oct 2020 08:05 |
| URI: | https://pred.uni-regensburg.de/id/eprint/30615 |
Actions (login required)
 |
View Item |
